There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
NCT01782703
Recruiting
Atopic dermatitis (AD), also known as eczema, is the most common inflammatory skin disorder of children, affecting 10-20% of children and 1-2% of adults. This skin disorder can be associated with unbearable itchiness and an increased susceptibility to skin infections. The cause of AD is currently poorly understood; therefore, there are no targeted treatment options at present. There have been recent studies in adults with AD that explain the cause and give us new routes to investigate treatment... Read More
Gender:
All
Ages:
Between 0 months and 17 years
Trial Updated:
03/11/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +3 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT05859724
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: First OC Dermatology Research, Fountain Valley, California +21 locations
Conditions: Atopic Dermatitis
Register for Updates
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
NCT05602207
Recruiting
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Inno-6050 Site 22, Birmingham, Alabama +11 locations
Conditions: Atopic Dermatitis
Register for Updates
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
NCT06259669
Recruiting
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Gender:
Female
Ages:
Between 15 years and 50 years
Trial Updated:
03/04/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Bodewell Products for the Treatment of Atopic Dermatitis
NCT05566262
Recruiting
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/28/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
NCT00568997
Recruiting
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
02/22/2024
Locations: Registry, Philadelphia, Pennsylvania
Conditions: Atopic Dermatitis
Register for Updates
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
NCT00177268
Recruiting
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Register for Updates
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +39 locations
Conditions: Atopic Dermatitis
Register for Updates
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
NCT05436535
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
01/31/2024
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California +9 locations
Conditions: Atopic Dermatitis
Register for Updates
POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis
NCT05932654
Recruiting
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections, as monotherapy or as add-on therapy with dupilumab. The study will enroll patients with moderate to severe AD in 4 cohorts. There will be 2 Monotherapy Cohorts, assigned to different doses of BSI-045B: a 300 mg Cohort and a 480 mg Cohort. There will be 2 Add-on Therapy Cohorts, assigned to different... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2024
Locations: First OC Dermatology - Fountain Valley, Fountain Valley, California +16 locations
Conditions: Atopic Dermatitis
Register for Updates
Registry for Systemic Eczema Treatments
NCT06136767
Recruiting
The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.
Gender:
All
Ages:
Between 1 year and 26 years
Trial Updated:
01/18/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Atopic Dermatitis
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Birmingham, Alabama +26 locations
Conditions: Atopic Dermatitis
Register for Updates